LABT Stock Catalyst: Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data

Jul 22, 2026 · 8:02am ET

Company responds to National Action Plan on antibiotic resistance.

Max move

+317.1%

High of day $7.80

Sparker timei

8:02am ET

LABT · Jul 22, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: LABT) announced the presentation of data on Nu-3 resistance in response to the National Action Plan of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria. The announcement was made to underscore the company's commitment to addressing antibiotic resistance.

The data presentation highlights the effectiveness of Nu-3 in combating resistant bacteria, aligning with the council's initiatives to tackle this growing healthcare challenge. The company's efforts are part of a broader strategy to develop innovative biotherapeutic solutions.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time LABT sparks.

Download Sniper App →

Catch the next LABT-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →